Results 11 to 20 of about 51,276 (310)
Rivaroxaban and Hemostasis in Emergency Care [PDF]
Emergency Medicine International, 2014 Rivaroxaban is an oral, direct Factor Xa inhibitor, approved for the prevention and treatment of several thromboembolic disorders. Rivaroxaban does not require routine coagulation monitoring and has a short half-life. However, confirmation of rivaroxaban
Jürgen Koscielny, Edita Rutkauskaite
doaj +4 more sources
Rivaroxaban in COMPASS trial [PDF]
Vnitřní lékařství, 2020 Cardiovascular diseases (CVD) are still at the first place in the case of mortality in European countries. Consistent secondary prevention for CVD is very important aspect in the fight with this negative statistics. We consider antithrombotic treatment as a gold standard in secondary prevention for CVD .
Miroslav Souček, Filip Šustr
openaire +3 more sources
Clinical medicine. Blood disorders, 2010 Anticoagulants are recommended for the prevention and treatment of venous thromboembolism (VTE). The new anticoagulants which target specific factors in the coagulation cascade offer the advantage that they can be administered orally. These drugs seek to offer safe anticoagulation without the need for regular monitoring and frequent dose adjustment ...
Osama M Moussa +2 more
openaire +4 more sources
Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban. [PDF]
, 2020 Background Reducing major bleeding events is a challenge when managing anticoagulation in patients with atrial fibrillation. This study evaluated the impact of modifiable and nonmodifiable bleeding risk factors in patients with atrial fibrillation ...
Amarenco, P +8 more
core +2 more sources
Journal of Prescribing Practice, 2021 In this column, Sharon Rees aims to refresh knowledge and interest in some of the commonly used drugs in a series of tweets. This month she is talking about #rivaroxaban
openaire +1 more source
Rivaroxaban and retropharyngeal haemorrhage [PDF]
BMJ Case Reports, 2016 Haemorrhage is a well-known and accepted complication of anticoagulation. A retropharyngeal haemorrhage (RH) is a rare condition that without prompt recognition and management may result in fatal complications. We report a case of RH in a 67-year-old man anticoagulated with rivaroxaban for atrial fibrillation.
Jonathan Andrew McCarter +3 more
openaire +3 more sources
XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation. [PDF]
, 2014 Atrial fibrillation (AF) is associated with a fivefold increase in the risk of stroke. The Phase III ROCKET AF (Rivaroxaban Once-Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in ...
Amarenco, P +6 more
core +2 more sources
Rivaroxaban in Stable Cardiovascular Disease [PDF]
New England Journal of Medicine, 2018 A response to "Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease" N Engl J Med 2017; 377:1319-1330.
Fauchier, Laurent +2 more
openaire +9 more sources
Patient safety and estimation of renal function in patients prescribed new oral anticoagulants for stroke prevention in atrial fibrillation [PDF]
, 2013 OBJECTIVE: In clinical trials of dabigatran and rivaroxaban for stroke prevention in atrial fibrillation (AF), drug eligibility and dosing were determined using the Cockcroft-Gault equation to estimate creatine clearance as a measure of renal function ...
Ashman, N +6 more
core +3 more sources
Rivaroxaban versus warfarin for the management of left ventricle thrombus
The Egyptian Heart Journal, 2021 Background Rivaroxaban has been recently introduced for the management of non-valvular intra-cardiac thrombosis with variable results. We aimed to compare the results of the off-label use of rivaroxaban versus warfarin in the management of patients with ...
Monirah A. Albabtain +7 more
doaj +1 more source